Associations - CBL mutation

CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
CBL mutation CBL mutation	Acute Myelogenous Leukemia AML	CBL mutation CBL mutation	Acute Myelogenous Leukemia AML	gilteritinib Resistant: B - Late Trials	gilteritinib Resistant: B - Late Trials
CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	CBL mutation CBL mutation	Myelodysplastic Syndrome MDS	quizartinib Sensitive: C2 – Inclusion Criteria	quizartinib Sensitive: C2 – Inclusion Criteria
CBL mutation CBL mutation	Acute Myelogenous Leukemia AML	CBL mutation CBL mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials	cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
CBL mutation CBL mutation	Sarcoma Sarcoma	CBL mutation CBL mutation	Sarcoma Sarcoma	MGCD516 Sensitive: C3 – Early Trials	MGCD516 Sensitive: C3 – Early Trials
CBL mutation CBL mutation	Non Small Cell Lung Cancer NSCLC	CBL mutation CBL mutation	Non Small Cell Lung Cancer NSCLC	MGCD516 Sensitive: C3 – Early Trials	MGCD516 Sensitive: C3 – Early Trials
CBL mutation CBL mutation	Melanoma Melanoma	CBL mutation CBL mutation	Melanoma Melanoma	MGCD516 Sensitive: C3 – Early Trials	MGCD516 Sensitive: C3 – Early Trials
CBL mutation CBL mutation	Non Small Cell Lung Cancer NSCLC	CBL mutation CBL mutation	Non Small Cell Lung Cancer NSCLC	SU11274 Sensitive: D – Preclinical	SU11274 Sensitive: D – Preclinical
CBL mutation CBL mutation	Chronic Myelomonocytic Leukemia CMML	CBL mutation CBL mutation	Chronic Myelomonocytic Leukemia CMML	dasatinib Sensitive: D – Preclinical	dasatinib Sensitive: D – Preclinical